Zoetis Inc. (NYSE:ZTS) Shares Sold by Savvy Advisors Inc.

Savvy Advisors Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,184 shares of the company’s stock after selling 194 shares during the period. Savvy Advisors Inc.’s holdings in Zoetis were worth $231,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. First Personal Financial Services acquired a new position in Zoetis in the 3rd quarter worth $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter worth about $33,000. Quarry LP boosted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC acquired a new stake in Zoetis during the 1st quarter valued at approximately $43,000. Finally, Fortitude Family Office LLC increased its holdings in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ZTS shares. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Stock Up 1.9 %

Shares of Zoetis stock opened at $177.28 on Thursday. The stock has a market capitalization of $79.98 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The business’s 50 day simple moving average is $187.81 and its 200-day simple moving average is $180.04.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the company earned $1.36 earnings per share. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.